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Abstract
Background: Depression is a common source of human disability for which etiologic insights remain limited. Although
abnormalities of monoamine neurotransmission, including dopamine, are theorized to contribute to the pathophysiology of
depression, evidence linking dopamine-related genes to depression has been mixed. The current study sought to address
this knowledge-gap by examining whether the combined effect of dopamine polymorphisms was associated with
depressive symptomatology in both healthy individuals and individuals with depression.
Methods: Data were drawn from three independent samples: (1) a discovery sample of healthy adult participants (n=273);
(2) a replication sample of adults with depression (n=1,267); and (3) a replication sample of healthy adult participants
(n=382). A genetic risk score was created by combining functional polymorphisms from five genes involved in synaptic
dopamine availability (COMT and DAT) and dopamine receptor binding (DRD1, DRD2, DRD3).
Results: In the discovery sample, the genetic risk score was associated with depressive symptomatology (b=20.80,
p=0.003), with lower dopamine genetic risk scores (indicating lower dopaminergic neurotransmission) predicting higher
levels of depression. This result was replicated with a similar genetic risk score based on imputed genetic data from adults
with depression (b=20.51, p=0.04). Results were of similar magnitude and in the expected direction in a cohort of healthy
adult participants (b=20.86, p=0.15).
Conclusions: Sequence variation in multiple genes regulating dopamine neurotransmission may influence depressive
symptoms, in a manner that appears to be additive. Further studies are required to confirm the role of genetic variation in
dopamine metabolism and depression.
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Introduction
Although depression is one of the most prevalent and costly
psychiatric conditions, estimated to affect 16.6% of US adults [1],
knowledge of its etiology remains limited. Currently, the most
commonly articulated theory regarding the pathophysiology of
depression focuses on systems regulating monoamine neurotrans-
mission [2]. This theory postulates that dysregulation of mono-
amine neurotransmission increases susceptibility to depression.
Serotonin has been the most frequently studied monoamine to
date. However, evidence from human and animal studies suggests
that other monoamines, particularly dopamine, may be involved
[3,4,5,6,7,8,9,10,11]. Chronic antidepressant treatment potenti-
ates the dopamine system [3]. In rodents, dopaminergic neurons
modulate depressive symptoms [4]. Disturbances in limbic
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Parkinson’s disease (PD) [5], and dopaminergic therapy for PD
can reduce depressive symptoms even in the absence of formal
antidepressant treatment [6]. Based on such findings, dopaminer-
gic targets have become a focus for depression therapies; one study
found that the DRD2 agonist pramipexole was as effective as
fluoxetine in the treatment of MDD [12]. Thus, a decreased level
of endogenous dopaminergic neurotransmission might make a
significant contribution to depression pathology. Another method
by which decreased dopaminergic neurotransmission might
increase depressive symptoms is through its influence on motiva-
tion and reward processing, both of which are impaired in
depression [13,14] and are strongly linked to the dopamine system
[15,16,17,18].
Examination of the effect of dopamine-related genetic variants
may extend knowledge of the role of dopamine neurotransmission
in the etiology and course of depression. This line of research is
warranted, as depression is highly heritable [19] and several
genetic variants have been found to modulate endogenous
dopamine neurotransmission [20,21,22,23]. Thus far, evidence
on the role of variation in dopamine neurotransmission in
depression has been mixed. While some studies find that
dopamine-related variants are associated with multiple psychiatric
and neurological diseases [24,25,26,27,28,29], other studies find
no association [9,30]. Moreover, when dopamine-related poly-
morphisms have been studied in the context of genome-wide
association studies (GWAS), none have emerged as significantly
associated with depression [31,32,33]. One likely contributor to
these inconsistent findings is that common genetic variants for
complex disease tend to have small to modest effects. Thus, tests of
association based on a single nucleotide polymorphism (SNP) are
unlikely to yield significant effects unless very large samples are
studied.
We sought to provide additional evidence regarding the role of
dopamine in depression by examining the combined effect of five
dopamine-related polymorphisms and depressive symptom sever-
ity. We used a genetic risk score approach, which sums the effects
of multiple polymorphisms in the same biological system. Genetic
risk score approaches have been informative in several medical
[34,35] and psychiatric [36,37] settings, including when studying
the role of dopamine [38,39,40]. The genetic risk score employed
in the current study captures genetic variation in several aspects of
the brain dopamine system, including synaptic dopamine avail-
ability (COMT and DAT) and dopamine receptor binding (DRD1,
DRD2, DRD3). These proteins are abundant in the cortical and
subcortical neural structures affected in depressive disorders
[10,11]. The genetic risk score employed in this analysis has been
linked to learning a motor skill and the extent to which oral L-
dopa supplementation improves this learning [39].
Materials and Methods
Overview
The main hypothesis we sought to test was that genetic variation
in the dopamine system was significantly related to depressive
symptoms, with genotypes corresponding to lower dopamine
neurotransmission being associated with greater depressive symp-
tomatology. We further hypothesized that the genetic risk score
would have a stronger relationship to depression than would any
single polymorphism, as the effects of multiple polymorphisms
acting on the same neural system are hypothesized to be additive.
We tested these hypotheses in a discovery sample of prospectively
enrolled healthy participants and in two replication samples. The
first replication cohort comprised individuals diagnosed with
major depressive disorder (MDD) from the Sequenced Treatment
Alternatives to Relieve Depression Study (STAR*D) [41,42,43].
The second replication was attempted using healthy subject data
from the Brain Genomics Superstruct Project (GSP) [44,45].
Discovery Sample: Healthy Young Adults
The discovery study was conducted in healthy young adults
between the ages of 18–35. This Healthy Study (HS) included 273
participants who were recruited from the University of California,
Irvine campus and surrounding areas.
Protocol. Participants were eligible for the HS if they were
between ages 18–35, right-handed, not taking dopamine-activat-
ing medications, and free of any current or past major neurological
or psychological disorder, assessed by self-report. Participants
underwent a blood draw for DNA collection and completed a
battery of supervised self-reported measures on health history,
demographic data, and the 20-item Center for Epidemiologic
Studies Depression Scale (CES-D). The CES-D is a widely used,
reliable, and valid measure of depression designed for use in
population-based studies [46]. Higher CES-D scores indicate
higher levels of depressive symptoms in the past week.
Ethics statement. Participants provided written informed
consent. The HS was approved by the Institutional Review Board
of the University of California, Irvine.
Genotyping. DNA was extracted from whole blood by salt
precipitation. Genotyping for all polymorphisms was performed
using polymerase chain reaction (PCR) - restricted fragment length
polymorphism analysis. PCR products were digested with the
appropriate restriction enzymes, digestion products were run on
agarose gel and then visualized with ethidium bromide. Choice of
primer sequences and digestion enzymes followed established
protocols for the five polymorphisms examined: COMT rs4680
[47], DAT rs28363170 [48], DRD1 rs4532 [49], DRD2/ANKK1
rs1800497 [50], and DRD3 rs6280 [51].
Calculating the dopamine genetic risk score. A dopa-
mine genetic risk score was created, representing the additive
effect of five polymorphisms related to dopaminergic neurotrans-
mission. A total of five polymorphisms were selected from
literature review based on (1) minor allele frequency .0.25 and
(2) strong association with biological measures ([39], see also
below). Participants were given a score of one for each allele
present that increases dopamine neurotransmission (Table 1).
Genetic risk scores could thus range from zero (lowest basal
dopamine neurotransmission) to 10 (highest basal dopamine
neurotransmission).
To create the genetic risk score, participants had one point
added to their score for each dopamine-increasing allele that they
possess at each of 5 polymorphic sites. This method is very similar
to that used by Stice et al [40], Nikolova et al [38] and Pearson-
Fuhrhop et al [39].
Classification of dopamine variants. 1. COMT (rs4680,
chromosome 22): COMT is an enzyme that degrades catechol-
amines such as dopamine, and has a val
158met polymorphism in
which the val allele results in a protein with 3–4 times lower
enzymatic activity, and thus higher dopaminergic tone [22]. In a
positron emission tomography (PET) study, F-Dopa metabolism
was greater in individuals with the COMT val/val genotype,
compared to met/met, within several cortical areas [52]. This
suggests that dopamine is metabolized faster, and therefore less
available, in individuals with the val/val genotype. Presence of the
158met variant has been associated with greater working memory
and more efficient prefrontal cortex physiology in humans [24].
Each
158met allele increases dopamine neurotransmission. There-
fore, one point was added to a participant’s genetic risk score for
Dopamine Genetic Risk Score Predicts Depression
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genotype was coded as 1) and Val/Val individuals (G/G genotype)
were given a score of 0. In the HS sample, a total of 38
participants had the Met/Met genotype, 129 Val/Met and 106
had Val/Val.
2. DAT (rs28363170, chromosome 5): DAT is an enzyme that
removes synaptic dopamine. The gene that encodes DAT has a
40 bp variable number of tandem repeats (VNTR) at the 39
untranslated region that commonly occurs in either 9 or 10
repeats. Several studies have shown that the 10-repeat allele is
related to higher expression of the DAT gene, which results in
lower dopaminergic tone [20]. Increased DAT activity is impli-
cated in the pathology of attention deficit hyperactivity disorder
(ADHD), considered a hypodopaminergic state, and stimulants
such as methylphenidate, which inhibit DAT and increase
dopamine levels, are often effective in treating ADHD. Consistent
with these findings, the 10-repeat allele has been associated with
ADHD [53]. Given these findings, participants received a score of
one for each 9 repeat, which produces a relatively higher level of
dopamine neurotransmission; those with the 10/10 genotype were
therefore scored as zero. In the HS sample, 97.1% had either 10/
10, 9/10, or 9/9 genotypes. However, 2.9% of participants (n=8)
had larger (11) and smaller (6, 7, 8) repeats. DAT 11-repeat alleles
behave more similarly to 10-repeat alleles [54], and another study
found that both 7- and 9-repeat alleles resulted in less DAT
activity than the 10-repeat allele [55]. Therefore, larger repeats
were coded as 0 and smaller repeats were coded as 1. In the HS
sample, a total of 190 participants had the 10/10 genotype, 66 had
9/10, 8 had 9/9, 2 had 11/10, 4 had 6/10, 1 had 7/10 and 1 had
8/10.
3. DRD1 (rs4532, chromosome 5): DRD1 is a dopamine receptor
and its gene has a 248 A/G SNP in the 59 untranslated region
[56]. Some studies suggest that the DRD1 G allele may be
associated with increases in brain dopamine neurotransmission.
For example, the G allele is more common in persons with bipolar
disorder [28], is associated with an increased rate of nicotine
dependence [25], and has been implicated in traits such as
compulsive eating, shopping, and gambling, all of which are linked
to increased brain dopaminergic tone [26]. For these reasons,
participants had one point added to their score for each G allele
(e.g., G/G genotype received a score of 2; A/G genotype received
a score of 1; A/A genotype received a score of 0). In the HS
sample, a total of 21 participants had the G/G genotype, 101 had
G/A and 151 had A/A.
4. DRD2 (rs1800497, chromosome 11): The ANKK1 TaqIA
polymorphism, a Glu to Lys substitution at position 713 of the
ANKK1 protein, near DRD2, is associated with a 30–40%
reduction in striatal D2 binding in post-mortem brain tissue, with
Lys carriers showing significantly lower D2 binding than Glu/Glu
homozygotes [23]. PET st udies have also found reduced striatal
D2 receptor availability with the Lys allele [57]. The Lys allele is
also associated with predisposition to neuroleptic malignant
syndrome, a hypodopaminergic state [27]. This suggests that
behaviorally, the Lys allele is more common in individuals who
have a condition characterized by an overall decrease in brain
dopaminergic signaling. Despite the opposing molecular effects of
dopamine binding at D1 and D2 receptors, behavioral evidence
suggests that DRD1 and DRD2 act in synergy [58,59,60,61], and
that the regulatory balance of dopamine signaling is optimized
when these two receptor types work in concert [58]. Therefore, a
polymorphism that decreases the amount of D2 receptor
availability and/or binding will likely still have the same
behavioral effect as one that decreases central dopaminergic
activity, as seen with the association between the A1 allele and
neuroleptic malignant syndrome [27]. Given these findings, one
point was added to a participant’s score for each Glu (A2) allele
present (e.g., G/G genotype received a score of 2; A/G genotype
received a score of 1; A/A genotype received a score of 0). In the
HS sample, a total of 23 participants had the Lys/Lys genotype,
115 had Lys/Glu and 135 had Glu/Glu.
5. DRD3 (rs6280, chromosome 3): DRD3 is a dopamine receptor
that has a SNP resulting in a Ser to Gly substitution at position 9 of
the protein. Dopamine has an affinity to the Gly variant that is 4–5
times higher than its affinity to the Ser variant, and in response to
dopamine the Gly variant more robustly increases cAMP
inhibition [21]. Initial classification of the
9Gly DRD3 polymor-
phism was based in part on a study that reported an increased risk
of tardive dyskinesia, a dopamine supersensitive state [62],
although this association was less clear upon subsequent meta-
analysis [63]. Further support for this classification of the
9Gly
DRD3 allele comes from Savitz et al, who found that participants
with the
9Gly allele showed increased striatal reward-related
dopamine release during a gambling task [64]. Any presence of the
9Gly DRD3 variant increases dopamine neurotransmission, and
thus one point was added for each Gly allele present (e.g., C/C
genotype received a score of 2; C/T genotype received a score of
1; T/T genotype received a score of 0). In the HS sample, a total
of 32 participants had the Gly/Gly genotype, 123 had Gly/Ser
and 118 had Ser/Ser.
Data analysis. Statistical tests were performed using JMP 8
statistical software (SAS, Cary, NC). Linear regression analysis was
used to examine the association between the genetic risk score and
depressive symptoms, adjusting for self-reported race/ethnicity. A
second linear regression model was used to assess the effect of the
genetic risk score on depression, controlling for age (continuous)
and gender (0=male, 1=female) as well as race/ethnicity. Next, a
‘‘leave one out’’ approach was examined to determine if the
association between the genetic risk score and depression
remained significant when removing each gene from the score,
one at a time; this approach tests whether any single variant is
driving the associations with the dopamine genetic risk score. In all
cases, race/ethnicity was included as a covariate. Hardy-Weinberg
equilibrium was confirmed for each gene using Chi-squared tests.
All participants had full genetic data available. CES-D scores were
Table 1. Summary of polymorphisms and classification for the genetic risk score.
Scoring System DRD1 DRD2 DRD3 COMT DAT
(rs4532) (rs1800497) (rs6280) (rs4680) (rs28363170)
0 A/A Lys/Lys Ser/Ser Val/Val 10/10
1 A/G Glu/Lys Ser/Gly Val/Met 9/10
2 G/G Glu/Glu Gly/Gly Met/Met 9/9
doi:10.1371/journal.pone.0093772.t001
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were within reasonable limits (skew=1.5, kurtosis=3.3 [65]), we
did not conduct any transformations of the data.
Replication Sample: STAR*D
The first replication attempt used data from the Sequenced
Treatment Alternatives to Relieve Depression Study (STAR*D;
[41,66]), which was designed to determine the psychopharmaco-
logical treatments most effective in treating depression.
Protocol. STAR*D was conducted at 41 clinical sites,
representing primary care or psychiatric outpatient clinics, across
the United States over a period of 37 months. The study only
enrolled individuals seeking treatment. To be eligible, participants
were required to have a clinical diagnosis of non-psychotic major
depressive disorder confirmed with a DSM-IV checklist and also
have a current score of 14 or higher on the 17-item Hamilton
Rating Scale of Depression (HAM-D; [67]). Higher HAM-D
scores indicate higher levels of depressive symptoms. To maximize
generalizability of the study results, participants with most
comorbid psychiatric and medical conditions were not excluded.
However, participants were excluded if they had a lifetime
diagnosis of major depressive disorder with psychotic features,
schizophrenia, schizoaffective disorder, or bipolar disorder I, II, or
not otherwise specified based on clinical assessment and self-report
(but not self-report questionnaires). A total of 4,041 participants
aged 18–75 were enrolled in STAR*D; 1,953 consented to provide
DNA samples for genomic analyses (see for example [68,69]). To
control for the effect of race/ethnicity, the current replication
analysis was restricted to the 1,267 individuals who self-reported
being White. Data for depressive symptoms was taken from
baseline, prior to treatment.
Ethics statement. Participants provided written, informed
consent. The STAR*D study was approved and monitored by the
institutional review boards at each participating institution
involved in the study, a National Coordinating Center, a Data
Coordinating Center, and the Data Safety and Monitoring Board
at the National Institute of Mental Health.
Genotyping. Genotyping was conducted on two different
platforms. About half of the sample was genotyped with the
Affymetrix GeneChip Human Mapping 500 K Array; the second
half was genotyped using the Affymetrix Genome-Wide Human
SNP 5.0 Array. A total of 500,568 SNPs were assayed by both
arrays. None of the genetic variants of interest in this study were
directly genotyped in STAR*D, though three SNPs (rs4680,
rs1800497, rs6280) were imputed from the HapMap (CEU
reference panel, release 23) using BEAGLE 3.3 [66]. These three
SNPs had imputation quality score of R
2 of .0.80.
Calculating the dopamine genetic risk score. Dosage
scores, obtained from imputation, were used to calculate the
genetic risk score, which was the sum of the risk allele counts for
the three variants included in this study. Higher values correspond
to greater levels of brain dopamine neurotransmisson. Only
participants with complete data for all variants were included in
the genetic risk score. A total of 126 respondents, or 9.94% of the
sample, were eliminated based on this criterion.
Data analysis. Genetic risk scores were calculated using
PLINK version 1.07. Analyses were conducted with SAS version
9.2, using a two-tailed alpha=0.05 for significance. Univariate
analyses were performed to describe the distribution of the genetic
risk scores, depressive symptoms, and demographic characteristics.
A linear regression model was then fit to estimate the association
between the genetic risk score and total symptoms of depression.
Depressive symptom scores were normally distributed. All analyses
controlled for age (continuous), sex (0=male; 1=female), marital
status (0=married/cohabiting; 1=never married; 2=divorced,
widowed, or separated), and principal components for genetic
ancestry. Data were cleaned using strict quality control methods as
described elsewhere [44].
Second Replication Sample: GSP
The second replication effort used data from the Brain
Genomics Superstruct Project (GSP), a large-scale study focusing
on the links between genes, brain function, and behavior in
healthy young adults [44,45].
Protocol. The GSP recruited healthy, native English-speak-
ing young adults, ages 18–35, from sites across Boston and
surrounding communities. To be eligible to participate, partici-
pants must not have had a history of head trauma, current or past
Axis I pathology or neurological disorder, current or past use of
psychotropic medications, acute physical illness, or a head injury
with loss of consciousness. Eligible participants completed a
structural and functional magnetic resonance imaging (MRI) scan,
provided a saliva sample (Oragene DNA Genotek) for the purpose
of DNA collection, and completed a set of health and
demographic questionnaires on the day of their MRI appoint-
ment. Participants were also invited to complete a set of optional
web-based instruments that measured personality, intelligence,
mood, and behavior. Mood was assessed using five items from the
shortened-version of the Profile of Mood States (POMS), which in
its complete form is a 30-item scale designed to assess affective
mood states, including depression, tension, anxiety, anger,
hostility, and confusion [70]. Respondents described their mood
in the past week using a Likert-scale (0=not at all to
4=extremely). Numerous factor analytic studies have derived
six-subscales or factors corresponding to these 30 items on the
POMS (see for example [70,71]; these six subscales are: tension-
anxiety; depression-dejection; anger-hostility; fatigue-inertia; vig-
or-activity; confusion-bewilderment. We examined the normalized
scores (t-scores) of the depression/dejection subscale of the POMS,
which consisted of five items and had good internal consistency
reliability (.0.90) [70,72].
Ethics statement. Investigators obtained written informed
consent from participants. All study procedures were approved by
the Institutional Review Board at Partners Health Care and
Harvard University.
Genotyping. Participants were genotyped using the Illumina
Infinium OMNI 1 quad chip, which after quality control captured
763,104 SNPs. Three of the genetic variants of interest in the
current study were directly genotyped (rs4680, rs6280, and
rs4532); one was imputed (rs1800497). A total of 470 participants
were genotyped, all of whom were White by self-report; of these,
442 had genetic data that passed quality control. Imputation was
completed using MACH (http://www.sph.umich.edu/csg/
abecasis/MACH/tour/imputation.html) and the 1000 Genomes
European data (phase 1 release v3) was used as the reference. The
ChunkChromosome program was used to split each chromosome
into 10 pieces, for which all GSP participants were imputed as one
batch. The imputation quality score R
2 of 0.80 was used in
filtering; all imputed SNPs had R
2.0.99.
Calculating the dopamine genetic risk score. The genetic
risk score was calculated from four of the available variants using
PLINK version 1.07. Only participants with complete genetic,
phenotypic, and covariate data were included. Based on these
criteria, 381 respondents were included in the analysis (13.8%
were excluded).
Data analysis. We conducted analyses with SAS version 9.2
(alpha 0.05 was the level of statistical significance). We began by
conducting univariate analyses to describe the distribution of the
Dopamine Genetic Risk Score Predicts Depression
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fit a linear regression model to estimate the association between
the genetic risk score and depressed mood score. Depressed mood
scores were slightly skewed towards lower values; as skew and
kurtosis values were within reasonable limits (skew=1.16;
kurtosis=1.01) [65], we did not conduct any transformations.
All analyses controlled for age (continuous), sex (0=male;
1=female), and principal components for genetic ancestry. As
described previously [68], the data were cleaned using several
quality control standards.
Results
Discovery Cohort: Healthy Young Adults
Demographic characteristics of participants in the HS sample
are presented in Table 2. The average CES-D score (out of a
possible range of 0–60) was 8.766.5. The sample was predom-
inately Asian (49%) and White (30%). All polymorphisms were in
Hardy-Weinberg equilibrium (rs4680: x
2=0.016, p=0.90;
rs4532: x
2=0.51, p=0.48; rs6280: x
2=0.00, p=0.995;
rs1800497: x
2=0.046, p=0.83). In the HS sample, the dopamine
genetic risk score was significantly associated with CES-D score
after adjusting for race/ethnicity (b=20.80, p=0.003), with
lower genetic risk scores corresponding to greater levels of
depression (Figure 1, Table 3). When controlling for the additional
covariates sex and age, the association between genetic risk score
and CES-D score remained significant (b=20.75, p=0.005).
When the 8 participants with uncommon DAT genotypes were
excluded from analyses, these associations remained significant
(b=20.79, p=0.004; b=20.74, p=0.006).
We conducted several exploratory analyses in the HS popula-
tion, including an examination of single variant effects, as well as a
set of 4-gene genetic risk scores generated using a ‘‘leave one out’’
approach. All of these exploratory models controlled for race/
ethnicity. In the examination of single variant effects (see Table 4),
we found that two individual variants were correlated with CES-D
score: the DRD2/ANKK1 Lys (A1) allele (b=21.6, p=0.01), and
the DRD3 Ser allele (b=21.1 p=0.06) were each individually
associated with higher depression scores, though only DRD2/
ANKK1 was statistically significant and remained so after adjusting
for multiple comparisons using a Bonferroni-corrected a=0.01.
Thus the genetic risk score showed a greater statistically significant
relationship to depression than was found with any single
polymorphism. Finally, results of the ‘‘leave one out’’ approach,
in which we removed one variant at a time from the genetic risk
score, revealed that the adjusted association between the genetic
risk score and depression remained significant for all five of the 4-
gene iterations of the dopamine genetic risk score. Thus no single
variant appeared to be driving the score, as the genetic risk score
remained statistically significant when omitting any one gene,
including DRD2/ANKK1.
In order to create a simplified score, containing the minimum
number of SNPs that still explains the CES-D scores, we examined
a 3-gene score with the 3 individual SNPs that had the highest
individual b values (Table 4). This 3-gene score was significantly
associated with CES-D score (b=21.19, p=0.0009). We also
examined the r
2 value for the model across the three most
significant predictors and found the largest r
2 value occurred with
this 3-gene score (r
2=0.092), intermediate for the 5-gene score
(r
2=0.085) and lowest for DRD2/ANKK1 alone (r
2=0.078),
though all of these values are similar.
Replication Results: STAR*D
Descriptive statistics are presented in Table 2. Depression scores
on the HAM-D ranged from 14 to 38 (mean=22.24, sd=4.9). In
analyses adjusted for principal components only, the genetic risk
score was significantly associated with depressive symptoms (b=2
0.50, p=0.05) in the expected direction, with lower dopamine
scores (indicating decreased dopamine transmission) being associ-
ated with greater levels of depression. After adjusting for all
covariates, this association remained statistically significant (b=2
0.51, p=0.04; Table 3).
As noted previously, the genetic risk score in the STAR*D
analyses used 3 of the 5 polymorphisms available in the analyses of
the HS dataset. In order to understand the potential impact of
studying only three polymorphisms, we created a score in the HS
sample that used only these three polymorphisms. When using
only these three polymorphisms, the genetic risk score remained
significantly associated with depression in the HS dataset (b=2
1.0, p=0.004).
Second replication results: GSP. Depressed mood t-scores
ranged from 32 to 67 (mean=40.18, sd=7.24; Table 2). The
genetic risk score was not significantly associated with depressive
symptoms in either the model adjusting only for principal
components (b=20.82, p=0.17) or the model adjusting for all
covariates (b=20.86, p=0.15). However, this association was in
the expected direction, with higher dopamine scores (indicating
Table 2. Demographic and baseline data.
HS STAR*D GSP
N 273 1267 381
Age 20.862.8 43.5613.5 21.3763.13
% Female 56.8% (N=155) 58.5% (N=745) 58% (N=221)
Average Genetic risk score 3.761.6 (1–8) 1.6360.6 (0–3) 1.4860.64 (0, 3.5)
Polymorphisms included rs4680 rs4680* rs4680
rs4532 rs6280* rs4532
rs6280 rs1800497* rs6280
rs1800497 rs1800497*
rs28363170
Data are shown as mean 6 SD (range).
*Denotes the SNP was imputed.
doi:10.1371/journal.pone.0093772.t002
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depression symptomatology (Table 3).
As the GSP used only 4 of the 5 polymorphisms available in the
analyses of the HS dataset, we created a score in the HS sample
that used only these four polymorphisms. When using only these
four polymorphisms, the genetic risk score was significantly
associated with depressive symptoms in the HS dataset (b=2
0.79, p=0.007).
Discussion
Given its public health burden, there is an urgent need to better
understand the etiology of depression and deploy this knowledge
to inform the development and implementation of effective
prevention and treatment efforts. However, depression is widely
considered to be a heterogeneous disorder consisting of multiple
subtypes (e.g., early vs. late onset) and symptom clusters (e.g., with
vs. without vegetative symptoms), which can reflect a number of
different underlying brain states [13,73]. Noninvasive methods
that capture biologically relevant inter-individual differences might
be useful to better understand the complex phenotype that is
depression.
Genetics offers one promising approach for identifying potential
biological differences between individuals and populations. In
particular, genetic investigations into the role of dopamine in
depression may help identify variants that give rise to elevated
susceptibility to the disorder. Prior research, from both human and
animal studies, has demonstrated links between dopamine
neurotransmission and depression [3,5,6]. Specifically, a reduction
in brain dopamine has been suggested as a contributor to
depressive symptoms [4,9,10,11,74,75]. Studies have also shown
that dopaminergic drugs, including pramipexole, have demon-
strated efficacy in the treatment of depression [12,76]. While these
studies collectively suggest that genetic variation in the proteins
related to brain dopamine neurotransmission are related to a
number of behavioral traits, our study was the first, to our
knowledge, to use a genetic risk score approach to examine the
relationship between multiple dopamine genetic variants and
depressive symptoms.
Results of the current study suggest that scores of functional
polymorphisms in dopaminergic genes corresponding to reduced
brain dopamine neurotransmission were significantly associated
with higher levels of depression in a sample of non-depressed
participants and in a large cohort of patients with depression. We
also found that these genetic influences appear additive. For
example, we found that the genetic risk score had a stronger
association with depressive symptoms than did any individual
gene. The strongest single genetic variant association was with the
DRD2/ANKK1 Taq1A Lys allele, though the p-value was weaker
for this variant than that found with the genetic risk score and the
4-gene score without DRD2/ANKK1 remained significant. Even
though the individual b value was relatively large for the DRD2/
ANKK1 polymorphism, the b values cannot be compared between
single genes and the multi-gene score given the differences in the
range of predictor values across models (i.e., the gene score
variable can range from 0–10 while the DRD2/ANKK1 variable
ranges from 0–2). The model using the 5-gene score explains more
of the variance in depressive symptoms than that using DRD2/
ANKK1 alone, as evidenced by the higher r
2 value. A strength of
the genetic risk score used in the current study is that it captures
several aspects of the dopamine system as a whole: levels of
synaptic dopamine, modulated by polymorphisms on the genes for
COMT and DAT, and binding of dopamine at three primary
dopamine receptor subtypes, modulated by polymorphisms
affecting these receptors. Important to the current hypotheses,
the proteins encoded by the five genes we examined are
abundantly present in the cortical and subcortical neural structures
affected in depression [10,11].
The score might be simplified by utilizing only the polymor-
phisms in DRD2/ANKK1, DRD3 and DAT. However, the use of
these 3 polymorphisms was data-driven, and therefore should be
verified in independent samples. A strength of the 5-gene score is
Table 3. Adjusted association between dopamine score and depressive symptoms.
Beta s.e. p-value 95% CI
HS 20.80 0.27 0.003 21.3, 20.27
STAR*D 20.51 0.25 0.04 20.99, 20.01
GSP 20.86 0.60 0.15 22.03, 0.31
Cell entries are beta coefficients, standard errors (s.e.), p-values and 95% confidence intervals (CI). The HS model controlled for race/ethnicity. The STAR*D model
contained controls for age (continuous), sex (0=male; 1=female); marital status (0=married/cohabiting; 1=never married; 2=divorced, widowed, or separated); and
five principle components for genetic ancestry/population stratification. The GSP model controlled for age (continuous), sex (0=male; 1=female), and four principle
components for genetic ancestry/population stratification. Depressive symptoms were measured by 3 scales: CES-D (HS), HAM-D (STAR*D), POMS short form (GSP).
doi:10.1371/journal.pone.0093772.t003
Figure 1. CES-D score by genetic risk score for the population
of HS participants. Results are mean 6 SE.
doi:10.1371/journal.pone.0093772.g001
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published literature.
In the HS study, each one unit difference in the genetic risk
score was negatively associated with a 0.80 difference in depressive
symptoms. Thus, an individual with the highest possible genetic
risk score (10) in this sample would be expected, based on the
regression model, to have an 8 point difference in their CES-D
score. This 8 point difference is clinically meaningful, as it is larger
than the difference between most categories used to differentiate
CES-D scores (i.e. no depression ranges from 0–9, mild depression
ranges from CES-D scores of 10–15, moderate depression ranges
from 16–24, and severe depression is above 25) [46].
An additional interesting aspect of the current study was that the
genetic risk score was related to the severity of depressive
symptoms in two groups with wide-ranging depression scores,
with a lower score related to higher depression both in healthy
undergraduates (HS study, mean CES-D score 8.7) and in patients
with a diagnosis of depression (STAR*D, mean HAM-D score
22.2, with all participants having major depression by study
design). Future studies can examine the robustness of the genetic
risk score across other conditions related to dopamine neurotrans-
mission, where it might have utility, for example, to provide
insights in the setting of Parkinson’s disease, where inter-individual
response to dopaminergic therapy is highly variable [77].
Theoretically, the dopamine genetic risk score could inform the
likelihood that a drug with dopaminergic activity would be an
effective antidepressant treatment choice for an individual patient.
Despite its strengths, the study has a number of limitations.
First, there was heterogeneity across the samples, with the two
replication samples having different measures of depressive
symptoms and different genes comprising the genetic risk score
when compared to the discovery cohort. For example, the genetic
score for STAR*D was estimated based on imputed SNPs,
compared to the discovery sample, which was based on genotyped
SNPs. Second, replication in the second healthy adult cohort
(GSP) failed to reach statistical significance, although results
(Table 3) trended in the same direction as with the two other
cohorts. This finding might reflect the fact that the 5-item POMS
depression subscale used in the GSP, which measures only current
mood state, lacked sufficient sensitivity to detect an association
with the dopamine genetic risk score. It may also reflect the
phenomenon known as the ‘‘winner’s curse’’, whereby the effect of
our genetic risk score could have been exaggerated in the
discovery sample compared to the two replication studies. Future
studies may be able to address this issue by examining more
detailed measures of depressive symptoms or its specific features
(e.g., anhedonia) as well as by examining whether the genetic risk
score predicts diagnoses of depression rather than depressive
symptoms. Third, the direction of correlation between the DAT 9/
10 polymorphism and depression is in the opposite direction of
that found in a meta-analysis by Lopez-Leon [30]. Mixed results
are common with this polymorphism and the reason for the
discrepancy is unclear. Fourth, dopamine effects are influenced by
numerous factors such as the dynamics and concentration of its
release [78], issues not examined in the current study. Fifth,
although a great deal of evidence indicates that environmental
factors may interact with genetic susceptibility to produce the final
affective/behavioral phenotype, i.e, whether or not an individual
will develop depression [79,80], we did not examine gene-
environment interactions in this study. Future studies might
therefore assess whether dopamine genetic risk score measures
interact with environmental factors in relation to depressive
symptomatology, and aim to identify which environmental factors
are most important. Sixth, we only examined a limited number of
genetic variants related to dopamine neurotransmission. Future
studies could examine whether genetic variation in proteins
subserving the neurotransmission of other brain monoamines
might also be important. Similarly, future efforts can examine
many more sources of genetic variation related to dopamine
neurotransmission, such as including additional polymorphisms in
DRD2, DRD4 or DARPP-32, for which evidence was more limited
at the time the HS study was designed. Finally, the three samples
differed in their makeup, calculation of the genetic risk score, and
assessment of depression symptoms. Though this means that they
may not reflect the truest ‘‘replication’’ of the original results, the
varied samples more accurately reflect the heterogeneity seen in
the general population and the clinical treatment of depression.
In summary, we found that a dopamine genetic risk score based
on functional polymorphisms with established effects on dopamine
neurotransmission was significantly associated with the level of
depressive symptoms in healthy participants and with depression
severity in participants with depressive disorder. This genetic risk
score shows stronger associations with the measures of depression
than does any single variant. Overall, the current findings support
models that emphasize a role for dopamine in the pathogenesis of
depressive symptoms and depressive disorder. Future research
should replicate these findings and determine whether the results
provide clinicians with new biological measures to improve clinical
decision-making for the initiation and selection of depression
therapies.
Acknowledgments
We thank Bhaskar Kolachana for assistance with setting up the COMT
assay. We also thank Pam Sevilla, Sahil Batra, Matin Khoshnevis, Maria
Frick, Vivian Ngo, Allen Nelson, Jacki Tran, Miriam Eshoiee, and Erin
Table 4. Adjusted association between individual dopamine variants and depressive symptoms.
HS Sample
Beta s.e. p-value 95% CI
rs4680 20.39 0.59 0.51 21.55, 0.77
rs4532 20.26 0.64 0.69 21.62, 1.10
rs6280 21.1 0.59 0.06 22.26, 0.06
rs1800497 21.6 0.62 0.01 22.82, 20.38
rs28363170 21.1 0.76 0.17 22.60, 0.40
Cell entries are beta coefficients, standard errors (s.e.), p-values and 95% confidence intervals (CI). The HS model controlled for race/ethnicity.
doi:10.1371/journal.pone.0093772.t004
Dopamine Genetic Risk Score Predicts Depression
PLOS ONE | www.plosone.org 7 May 2014 | Volume 9 | Issue 5 | e93772Burke for their assistance. We are also grateful to Randy Buckner for his
efforts on the GSP.
Author Contributions
Conceived and designed the experiments: KMPF ECD SM JWS JR SCC.
Performed the experiments: KMPF SM AJH MOH JLR SCC. Analyzed
the data: KMPF ECD SM WJD GJF AJH PL. Wrote the paper: KMPF
ECD JR SCC.
References
1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, et al. (2005)
Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the
National Comorbidity Survey Replication. Arch Gen Psychiatry 62: 593–602.
2. Hirschfeld RM (2000) History and evolution of the monoamine hypothesis of
depression. J Clin Psychiatry 61 Suppl 6: 4–6.
3. D’Aquila PS, Collu M, Gessa GL, Serra G (2000) The role of dopamine in the
mechanism of action of antidepressant drugs. Eur J Pharmacol 405: 365–373.
4. Tye KM, Mirzabekov JJ, Warden MR, Ferenczi EA, Tsai HC, et al. (2013)
Dopamine neurons modulate neural encoding and expression of depression-
related behaviour. Nature 493: 537–541.
5. Lieberman A (2006) Depression in Parkinson’s disease – a review. Acta Neurol
Scand 113: 1–8.
6. Erro R, Picillo M, Vitale C, Amboni M, Moccia M, et al. (2012) Non-motor
symptoms in early Parkinson’s disease: a 2-year follow-up study on previously
untreated patients. J Neurol Neurosurg Psychiatry.
7. Gershon AA, Vishne T, Grunhaus L (2007) Dopamine D2-like receptors and the
antidepressant response. Biol Psychiatry 61: 145–153.
8. Kapur S, Mann JJ (1992) Role of the dopaminergic system in depression. Biol
Psychiatry 32: 1–17.
9. Opmeer EM, Kortekaas R, Aleman A (2010) Depression and the role of genes
involved in dopamine metabolism and signalling. Prog Neurobiol 92: 112–133.
10. Dunlop BW, Nemeroff CB (2007) The role of dopamine in the pathophysiology
of depression. Arch Gen Psychiatry 64: 327–337.
11. Cabib S, Puglisi-Allegra S (1996) Stress, depression and the mesolimbic
dopamine system. Psychopharmacology 128: 331–342.
12. Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL (2000)
Comparison of pramipexole, fluoxetine, and placebo in patients with major
depression. Depress Anxiety 11: 58–65.
13. Nestler EJ, Carlezon WA, Jr. (2006) The mesolimbic dopamine reward circuit in
depression. Biol Psychiatry 59: 1151–1159.
14. Pizzagalli DA (2014) Depression, Stress, and Anhedonia: Toward a Synthesis
and Integrated Model. Annu Rev Clin Psychol.
15. Schultz W, Dayan P, Montague PR (1997) A neural substrate of prediction and
reward. Science 275: 1593–1599.
16. Salamone JD, Correa M (2012) The mysterious motivational functions of
mesolimbic dopamine. Neuron 76: 470–485.
17. Wise RA (2004) Dopamine, learning and motivation. Nat Rev Neurosci 5: 483–
494.
18. Wise RA (2009) Roles for nigrostriatal–not just mesocorticolimbic–dopamine in
reward and addiction. Trends Neurosci 32: 517–524.
19. Sullivan PF, Neale MC, Kendler KS (2000) Genetic epidemiology of major
depression: Review and meta analysis. Am J Psychiatry 157: 1552–1562.
20. Heinz A, Goldman D, Jones DW, Palmour R, Hommer D, et al. (2000)
Genotype influences in vivo dopamine transporter availability in human
striatum. Neuropsychopharmacology 22: 133–139.
21. Jeanneteau F, Funalot B, Jankovic J, Deng H, Lagarde JP, et al. (2006) A
functional variant of the dopamine D3 receptor is associated with risk and age-
at-onset of essential tremor. Proc Natl Acad Sci U S A 103: 10753–10758.
22. Mannisto PT, Kaakkola S (1999) Catechol-O-methyltransferase (COMT):
biochemistry, molecular biology, pharmacology, and clinical efficacy of the
new selective COMT inhibitors. Pharmacol Rev 51: 593–628.
23. Thompson J, Thomas N, Singleton A, Piggott M, Lloyd S, et al. (1997) D2
dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2
receptor binding in the human striatum associated with the A1 allele.
Pharmacogenetics 7: 479–484.
24. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, et al.
(2001) Effect of COMT Val108/158 Met genotype on frontal lobe function and
risk for schizophrenia. Proc Natl Acad Sci U S A 98: 6917–6922.
25. Huang W, Ma JZ, Payne TJ, Beuten J, Dupont RT, et al. (2008) Significant
association of DRD1 with nicotine dependence. Hum Genet 123: 133–140.
26. Comings DE, Gade R, Wu S, Chiu C, Dietz G, et al. (1997) Studies of the
potential role of the dopamine D1 receptor gene in addictive behaviors. Mol
Psychiatry 2: 44–56.
27. Mihara K, Kondo T, Suzuki A, Yasui-Furukori N, Ono S, et al. (2003)
Relationship between functional dopamine D2 and D3 receptors gene
polymorphisms and neuroleptic malignant syndrome. Am J Med
Genet B Neuropsychiatr Genet 117: 57–60.
28. Dmitrzak-Weglarz M, Rybakowski JK, Slopien A, Czerski PM, Leszczynska-
Rodziewicz A, et al. (2006) Dopamine receptor D1 gene 248A/G polymor-
phism is associated with bipolar illness but not with schizophrenia in a Polish
population. Neuropsychobiology 53: 46–50.
29. O’Tuathaigh CM, Desbonnet L, Lee P, Waddington JL (2012) Catechol-O-
methyl transferase as a drug target for schizophrenia. CNS Neurol Disord Drug
Targets 11: 282–291.
30. Lopez-Leon S, Janssens AC, Gonzalez-Zuloeta Ladd AM, Del-Favero J, Claes
SJ, et al. (2008) Meta-analyses of genetic studies on major depressive disorder.
Mol Psychiatry 13: 772–785.
31. Bosker FJ, Hartman CA, Nolte IM, Prins BP, Terpstra P, et al. (2011) Poor
replication of candidate genes for major depressive disorder using genome-wide
association data. Mol Psychiatry 16: 516–532.
32. Hek K, Demirkan A, Lahti J, Terracciano A, Teumer A, et al. (2013) A
Genome-Wide Association Study of Depressive Symptoms. Biol Psychiatry.
33. Major Depressive Disorder Working Group of the Psychiatric GWAS
Consortium (2012) A mega-analysis of genome-wide association studies for
major depressive disorder. Mol Psychiatry: 1–15.
34. Pharoah PD, Antoniou AC, Easton DF, Ponder BA (2008) Polygenes, risk
prediction, and targeted prevention of breast cancer. N Engl J Med 358: 2796–
2803.
35. Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, et al. (2008) Cumulative
association of five genetic variants with prostate cancer. N Engl J Med 358: 910–
919.
36. Purcell SM, Wray NR, Stone JL, Visscher PM, O’Donovan MC, et al. (2009)
Common polygenic variation contributes to risk of schizophrenia and bipolar
disorder. Nature 460: 748–752.
37. Roffman JL, Brohawn DG, Nitenson AZ, Macklin EA, Smoller JW, et al. (2013)
Genetic variation throughout the folate metabolic pathway influences negative
symptom severity in schizophrenia. Schizophr Bull 39: 330–338.
38. Nikolova YS, Ferrell RE, Manuck SB, Hariri AR (2011) Multilocus genetic
profile for dopamine signaling predicts ventral striatum reactivity. Neuropsy-
chopharmacology 36: 1940–1947.
39. Pearson-Fuhrhop KM, Minton B, Acevedo D, Shahbaba B, Cramer SC (2013)
Genetic variation in the human brain dopamine system influences motor
learning and its modulation by L-Dopa. PLoS One, in press.
40. Stice E, Yokum S, Burger K, Epstein L, Smolen A (2012) Multilocus genetic
composite reflecting dopamine signaling capacity predicts reward circuitry
responsivity. J Neurosci 32: 10093–10100.
41. Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase SE, et al. (2003)
Background and rationale for the sequenced treatment alternatives to relieve
depression (STAR*D) study. Psychiatr Clin North Am 26.
42. Rush AJ, Trivedi M, Fava M (2003) Depression, IV: STAR*D treatment for
depression. Am J Psychiatry 160: 237.
43. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, et al. (2006)
Evaluation of outcomes with citalopram for depression using measurement-
based care in STAR*D: Implications for clinical practice. Am J Psychiatry 163:
28–40.
44. Holmes AJ, Lee PH, Hollinshead M, Bakst L, Roffman JL, et al. (2012)
Individual differences in amygdala-medial prefrontal anatomy link negative
affect, impaired social functioning, and polygenic depression risk. J Neurosci 32:
18087–18100.
45. Yeo BTT, Krienen FM, Sepulcre J, Sabuncu MR, Lashkari D, et al. (2011) The
organization of the human cerebral cortex estimated by intrinsic functional
connectivity. J Neurophysiol 106: 1125–1165.
46. Radloff LS (1977) The CES-D Scale: A Self-Report Depression Scale for
Research in the General Population. Appl Psychol Meas 1: 385–401.
47. Berthele A, Platzer S, Jochim B, Boecker H, Buettner A, et al. (2005) COMT
Val108/158Met genotype affects the mu-opioid receptor system in the human
brain: evidence from ligand-binding, G-protein activation and preproenkephalin
mRNA expression. NeuroImage 28: 185–193.
48. Kang AM, Palmatier MA, Kidd KK (1999) Global variation of a 40-bp VNTR
in the 39-untranslated region of the dopamine transporter gene (SLC6A3). Biol
Psychiatry 46: 151–160.
49. Limosin F, Loze JY, Rouillon F, Ades J, Gorwood P (2003) Association between
dopamine receptor D1 gene DdeI polymorphism and sensation seeking in
alcohol-dependent men. Alcohol Clin Exp Res 27: 1226–1228.
50. Noble EP, St Jeor ST, Ritchie T, Syndulko K, St Jeor SC, et al. (1994) D2
dopamine receptor gene and cigarette smoking: a reward gene? Med Hypotheses
42: 257–260.
51. Woo SI, Kim JW, Rha E, Han SH, Hahn KH, et al. (2002) Association of the
Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive
dyskinesia in Korean schizophrenics. Psychiatry Clin Neurosci 56: 469–474.
52. Wu K, O’Keeffe D, Politis M, O’Keeffe GC, Robbins TW, et al. (2012) The
catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-
cortical dopamine turnover in early Parkinson’s disease: a PET study. Brain 135:
2449–2457.
53. Gilbert DL, Wang Z, Sallee FR, Ridel KR, Merhar S, et al. (2006) Dopamine
transporter genotype influences the physiological response to medication in
ADHD. Brain 129: 2038–2046.
Dopamine Genetic Risk Score Predicts Depression
PLOS ONE | www.plosone.org 8 May 2014 | Volume 9 | Issue 5 | e9377254. Inoue-Murayama M, Adachi S, Mishima N, Mitani H, Takenaka O, et al.
(2002) Variation of variable number of tandem repeat sequences in the 39-
untranslated region of primate dopamine transporter genes that affects reporter
gene expression. Neurosci Lett 334: 206–210.
55. Fuke S, Suo S, Takahashi N, Koike H, Sasagawa N, et al. (2001) The VNTR
polymorphism of the human dopamine transporter (DAT1) gene affects gene
expression. Pharmacogenomics J 1: 152–156.
56. Cichon S, Nothen MM, Erdmann J, Propping P (1994) Detection of four
polymorphic sites in the human dopamine D1 receptor gene (DRD1). Hum Mol
Genet 3: 209.
57. Pohjalainen T, Rinne JO, Nagren K, Lehikoinen P, Anttila K, et al. (1998) The
A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor
availability in healthy volunteers. Mol Psychiatry 3: 256–260.
58. Shen W, Flajolet M, Greengard P, Surmeier DJ (2008) Dichotomous
dopaminergic control of striatal synaptic plasticity. Science 321: 848–851.
59. Calhoon GG, O’Donnell P (2010) Many Roads to Motor Deficits: Loss of
Dopamine Signaling in Direct or Indirect Basal Ganglia Pathway Leads to
Akinesia through Distinct Physiological Mechanisms. Front Neurosci 4: 168.
60. Strange PG (1991) D1/D2 dopamine receptor interaction at the biochemical
level. Trends Pharmacol Sci 12: 48–49.
61. Waddington JL (1986) Behavioural correlates of the action of selective D-1
dopamine receptor antagonists. Impact of SCH 23390 and SKF 83566, and
functionally interactive D-1: D-2 receptor systems. Biochem Pharmacol 35:
3661–3667.
62. Bakker PR, van Harten PN, van Os J (2006) Antipsychotic-induced tardive
dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis.
Schizophr Res 83: 185–192.
63. Tsai HT, North KE, West SL, Poole C (2010) The DRD3 rs6280 polymorphism
and prevalence of tardive dyskinesia: a meta-analysis. Am J Med
Genet B Neuropsychiatr Genet 153B: 57–66.
64. Savitz J, Hodgkinson CA, Martin-Soelch C, Shen PH, Szczepanik J, et al. (2013)
The functional DRD3 Ser9Gly polymorphism (rs6280) is pleiotropic, affecting
reward as well as movement. PLoS One 8: e54108.
65. Tabachnick BG, Fidell LS (2013) Using multivariate statistics 6th edition.
Boston, MA: Allyn and Bacon.
66. Huang J, Perlis RH, Lee PH, Rush AJ, Fava M, et al. (2010) Cross-disorder
genomewide analysis of schizophrenia, bipolar disorder, and depression.
Am J Psychiatry 167: 1254–1263.
67. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry
23: 56–62.
68. Shyn SI, Shi J, Kraft JB, Potash JB, Knowles JA, et al. (2011) Novel loci for
major depression identified by genome-wide association study of STAR*D and
meta analysis of three studies. Mol Psychiatry 16: 202–215.
69. Garriock HA, Kraft JB, Shyn SI, Peters EJ, Yokoyama JS, et al. (2010) A
genome-wide association study of citalopram response in major depressive
disorder. Biol Psychiatry 67: 133–138.
70. McNair DM, Lorr M, Droppleman LF (1971) Manual: Profile of Mood States.
San Diego, CA: Educational and Industrial Testing Service.
71. Pollock V, Cho D, Reker D, Volavka J (1979) Profile of mood states: the factors
and their physiological correlates. J Nerv Ment Dis 167: 612–614.
72. Shacham S (1983) A shortened version of the profile of mood states. J Pers Assess
47: 305–306.
73. Maletic V, Robinson M, Oakes T, Iyengar S, Ball SG, et al. (2007) Neurobiology
of depression: an integrated view of key findings. Int J Clin Pract 61: 2030–2040.
74. Gershon AA, Vishne T, Grunhaus L (2007) Dopamine D2-like receptors and the
antidepressant response. Biol Psychiatry 61: 145–153.
75. Kapur S, Mann JJ (1992) Role of the dopaminergic system in depression. Biol
Psychiatry 32: 1–17.
76. Hori H, Kunugi H (2012) The efficacy of pramipexole, a dopamine receptor
agonist, as an adjunctive treatment in treatment-resistant depression: an open-
label trial. ScientificWorldJournal 2012: 372474.
77. Hauser RA, Auinger P, Oakes D (2009) Levodopa response in early Parkinson’s
disease. Mov Disord 24: 2328–2336.
78. Luft AR, Schwarz S (2009) Dopaminergic signals in primary motor cortex.
Int J Dev Neurosci 27: 415–421.
79. Lotrich FE (2011) Gene-environment interactions in geriatric depression.
Psychiatr Clin North Am 34: 357–376, viii.
80. Dunn EC, Uddin M, Subramanian SV, Smoller JW, Galea S, et al. (2011) Gene-
environment interaction (GxE) research in youth depression: A systematic review
with recommendations for future research. J Child Psychol Psychiatry 52: 1223–
1238.
Dopamine Genetic Risk Score Predicts Depression
PLOS ONE | www.plosone.org 9 May 2014 | Volume 9 | Issue 5 | e93772